You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Low Cost, Efficient Microchannel Plasma Ozone System for Point of Use Water Treatment
SBC: EP Purification, Inc. Topic: AA team at EP Purification has performed research for the development and commercialization of low-cost microchannel plasma reactor modules capable of efficiently producing ozone for water treatment and other environmental applications in a slim form factor and size. The conservation of water resources for human consumption is a growing national priority. Ozone is a unique purification agent as it ...
SBIR Phase II 2014 Environmental Protection Agency -
Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis
SBC: Exicure, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Human Induced Pluripotent Stem Cell-Derived Beta-Cells for Drug and Toxicity Testing
SBC: Regenerative Medical Solutions Inc Topic: NIDDK? DESCRIPTION (provided by applicant): Diabetes represents one of the most serious health crises worldwide. It is estimated by the American Diabetes Association that one person is diagnosed with diabetes every 17 seconds, while the International Diabetes Federation states that one person dies every seven seconds from diabetes. Diabetes growth continues to skyrocket, with over 382 million cases ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
High-Throughput Microdevice for Temporal Single-Cell Analysis
SBC: INFINITESIMAL, LLC Topic: NIGMSDESCRIPTION: Single-cell studies are essential for biochemical characterization of heterogeneous cell behaviors. However, studying direct correlation between cell input (transfection) and output (biochemical analysis) is still challenging due to lack of high throughpu methodologies with cell selectivity and high enough sensitivity. The tool proposed here is a microwell device that will allow tempo ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Activated hexosamines from chitin for production of important oligosaccharides
SBC: ZUCHEM INC. Topic: NIGMSDESCRIPTION (provided by applicant): UDP-GlcNAc and UDP-GalNAc comprise the core structures of glycans in glycoproteins and glycolipids. Oligosaccharides containing N-acetyl-hexosamines involved in various biological process, including microbial infection,toxin entry, cancer cell metastasis. They are the key building blocks for human milk oligosaccharides, blood antigens, and other important oligo ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecule Multi-targeted Ligands as Therapeutics for the Treatment of
SBC: JASIN DISCOVERY SOLUTIONS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Spinal Muscular Atrophy (SMA), a common autosomal recessive motor neuron disorder is the leading genetic cause of infant mortality. SMA is caused by the loss of the survival motor neuron1 (SMN1) gene. SMN2, a nearly identical paralog, is present in all SMA patients but differs by a critical nucleotide that alters exon 7 splicing efficiency. This results in low ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A proposal to develop a self-regulating hydromorphone tablet to deter excess oral
SBC: ACURA PHARMACEUTICALS, INC. Topic: NIDADESCRIPTION: The medical misuse and non-medical use of prescription opioid analgesics is a significant problem in USA and its societal effects and cost have been well documented. The emergence of abuse deterrent opioid products into the marketplace is targeted to stem the advance of this complex problem. Although new abuse deterrent opioid products have been introduced which deter manipulation of ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Using an API to commercialize an evidence-based weight loss intervention
SBC: COEUS HEALTH, LLC Topic: NIDDKDESCRIPTION (provided by applicant): Over 69 percent of the U.S. population is currently overweight or obese; 35 percent are obese. Obesity is a primary cause of numerous chronic diseases including type II diabetes, cancer, heart disease and the metabolicsyndrome. Behavioral weight loss interventions have successfully resulted in significant clinical improvements in weight (7-10 percent weight los ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis
SBC: Exicure, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells
SBC: IMMUVEN, INC. Topic: NCIProject Summary The goal of this STTR grant application is to engineer powerful NK cell-based cytolytic effector cells for therapeutic applications. The cells will combine the selectivity and specificity of T cells and the ability of NK cells to mediate effective cytolytic activity against a wide spectrum of aberrant cells, including those with impaired adhesion properties. To achieve this goal we ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health